Phase I study of peptides derived from novel cancer antigen using with Gemcitabine for advanced pancreatic cancer

Phase I study of peptides derived from novel cancer antigen using with Gemcitabine for advanced pancreatic cancer - Phase I study of peptides derived from novel cancer antigen using with Gemcitabine for advanced pancreatic cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007504

Enrollment

Registered

2012-03-17

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced pancreatic cancer

Interventions

Combination Epitope Peptides with gemcitabine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.pancreatic cancer 2.oldOne or more RECIST lesions 3.PS:0 to 2(ECOG performance status score) 4.age: over 20 years-old 5.Suspect for more than 3 months alive 6. 7.Good function of critical organs

Exclusion criteria

Exclusion criteria: 1. pregnant woman 2. 3. 4. 5. Steroid or immunosuppressive therapy 6. 7. 8.Doctors opinion

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
immune response One Year survival rate Two Year survival rate Completion rate Median Survival Time Overall survival Adverse Event	—

Countries

Japan

Contacts

Public ContactNobuaki Suzuki

YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE Department of Digestive Surgery and Surgical Oncology

0836-22-2264

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026